Antineutrophil cytoplasm autoantibodies in patients with tuberculosis are directed against bactericidal/permeability increasing protein and are detected after treatment initiation

Clinical and Experimental Rheumatology

Volumn 28, Issue 1 SUPPL. 57, 2010, Pages

  Esquivel Valerio, Jorge Antonio ^a   Flores Suárez, Luis Felipe ^c   Rodríguez Amado, Jacqueline ^a   Garza Elizondo, Mario Alberto ^a   Rendón, Adrian ^b   Salinas Carmona, Mario César ^b  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^c INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

ANCA; Mycobacterium infections; Pulmonary tuberculosis; Treatment; Vasculitis; Wegener's granulomatosis

Indexed keywords

BACTERICIDAL PERMEABILITY INCREASING PROTEIN; C REACTIVE PROTEIN; ETHAMBUTOL; ISONIAZID PLUS RIFAMPICIN; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; RIFATER; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ANTIMICROBIAL CATIONIC PEPTIDE; EPITOPE; PEROXIDASE; PLASMA PROTEIN; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNOFLUORESCENCE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; ANTIGEN SPECIFICITY; CAUSE OF DEATH; CLINICAL FEATURE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL HISTORY; PREVALENCE; SENSITIVITY ANALYSIS; TREATMENT INDICATION; BLOOD; EPIDEMIOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; MIDDLE AGED;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIMICROBIAL CATIONIC PEPTIDES; ANTITUBERCULAR AGENTS; BLOOD PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; MALE; MIDDLE AGED; MYELOBLASTIN; PEROXIDASE; SEROEPIDEMIOLOGIC STUDIES; TUBERCULOSIS, PULMONARY;

EID: 77954601587     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. VAN DER WOUDE FJ, RASMUSSEN N, LOBATTO S et al.: Autoantibodies against neutrophils and monocytes: Tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; 1: 425-9.
2. BOSCH X, GUILABERT A, FONT J: Antineutrophil cytoplasmic antibodies. Lancet 2006; 368: 404-18.
3. LAMPRECHT P, SCHMITT WH, GROSS WL: Mixed cryoglobulinaemia, glomerulonephritis, and ANCA: Essential cryoglobulinaemic vasculitis or ANCA-associated vasculitis? Nephrol Dial Transplant 1998; 13: 213-21.
4. SCHMITT WH, VAN DER WOUDE FJ: Clinical applications of antineutrophil cytoplasmic antibody testing. Curr Opin Rheumatol 2004; 16: 9-17.
5. KNIGHT A, EKBOM A, BRANDT L, ASKLING J: What is the significance in routine care of C-ANCA/PR3-ANCA in the absence of systemic vasculitis? A case series. Clin Exp Rheumatol: 2008; 26: S53-6.
6. FLORES-SUAREZ LF, CABlEDES J, VILLA AR, VAN DER WOUDE FJ, ALCOCER-VARELA J: Prevalence of antineutrophil cytoplasmic autoantibodies in patients with tuberculosis. Rheumatology 2003; 42: 223-9.
7. TEIXElRA L, MAHR A, JAUREGUY F et al.: Low seroprevalence and poor specificity of antineutrophil cytoplasmic antibodies in tuberculosis. Rheumatology 2005; 44: 247-50.
8. JIANG X, KHURSIGARA G, RUBIN RL: Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science 1994; 266: 810-3.
9. NASSBERGER L, SJOHOLM AG, JONSSON H, STURFELT G, AKESSON A: Autoantibodies against neutrophil cytoplasm components in systemic lupus erythematosus and in hydralazine-induced lupus. Clin Exp Immunol 1990; 81: 380-3.
10. ALOUSH V, LITINSKY I, CASPI D, ELKAYAM O: Propylthiouracil-induced autoimmune syndromes: Two distinct clinical presentations with different course and management. Semin Arthritis Rheum 2006; 36: 4-9.
11. BONACI-NIKOLIC B, NIKOLIC MM, ANDREJEVIC S, ZORIC S, BUKILICA M: Antineutrophil cytoplasmic antibody (ANCA-associated autoimmune diseases induced by antithyroid drugs: Comparison with idiopathic ANCA vasculitides. Arthritis Res Ther 2005; 7: R1072-81.
12. CHOI HK, SLOT MC, PAN G, WEISSBACH CA, NILES JL, MERKEL PA: Evaluation of antineutrophil cytoplasmic antibody seroconversion induced by minocycline, sulfasalazine, or penicillamine. Arthritis Rheum 2000; 43: 2488-92.
13. HILLIS GS, KHAN IH, SIMPSON JG, REES AJ: Scleroderma, D-penicillamine treatment, and progressive renal failure associated with positive antimyeloperoxidase antineutrophil cytoplasmic antibodies. Am J Kidney Dis 1997; 30: 279-81.
14. CHOI HK, MERKEL PA, WALKER AM, NILES JL: Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: Prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum 2000; 43: 405-13.
15. SCHULTZ H, CSERNOK E, HERLYN K et al.: ANCA against bactericidal/ permeability-increasing protein, azurocidin, calprotectin and defensins in rheumatic and infectious diseases: Prevalence and clinical associations. Clin Exp Rheumatol 2003; 21: S117-20.
16. LAWN SD, OBENG J, ACHEAMPONG JW, GRIFFIN GE: Resolution of the acute-phase response in west african patients receiving treatment for pulmonary tuberculosis. Im J Tuberc Lung Dis 2000; 4: 340-4.
17. SCHULTZ H, HEINTZ H, VAN ZANDBERGEN G, ULLRICH S, REINHOLD-KELLER E, GROSS WL: ANCA against the bactericidal/permeability increasing protein (BPI-ANCA) can compromise the antibiotic function of BPI in a Wegener's granulomatosis patient. Clin Exp Rheumatol 2003; 21: 763-6.
18. SCHULTZ H: From infection to autoimmunity: A new model for induction of ANCA against the bactericidal/permeability increasing protein (BPI). Autoimmun Rev 2007; 6: 223-7.
19. SCHULTZ H, CSERNOK E, SCHUSTER A, SCHMITZ TS, ERNST M, GROSS WL: Antineutrophil cytoplasmic antibodies directed against the bactericidal/ permeability-increasing protein (BPI) in pediatric cystic fibrosis patients do not recognize N-terminal regions important for the anti-microbial and lipopolysaccharide-binding activity of BPI. Pediatr Allergy Immunol 2000; 11: 64-70.
20. ELSBACH P, WEISS J: Role of the bactericidal/permeability-increasing protein in host defence. Curr Opin Immunol 1998; 10: 45-9.
21. SCHULTZ H, HUME J, ZHANG DS, GIOANNINI TL, WEISS JP: A novel role for the bactericidal/permeability increasing protein in interactions of Gram-negative bacterial outer membrane blebs with dendritic cells. J Immunol 2007; 179: 2477-84.
22. ARDITI M, ZHOU J, HUANG SH, LUCKETT PM, MARRA MN, KIM KS: Bactericidal/permeability-increasing protein protects vascular endothelial cells from lipopolysaccharide-induced activation and injury. Infect Immun 1994; 62: 3930-6.
23. JUFFERMANS NP, VERBON A, VAN DEVENTER SJ et al.: Serum concentrations of lipopolysaccharide activity-modulating proteins during tuberculosis. J Infect Dis 1998; 178: 1839-42.
24. JACOBSEN M, REPSILBER D, GUTSCHMIDT A et al.: Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J Mol Med 2007; 85: 613-21.
25. JO EK, YANG CS, CHOI CH, HARDING CV: Intracellular signaling cascades regulating innate immune responses to Mycobacteria: branching out from Toll-like receptors. Cell Microbiol 2001; 9: 1087-98.
26. DENTENER MA, FRANCOT GJ, HIEMSTRA PS et al.: Bactericidal/permeability- increasing protein release in whole blood ex vivo: Strong induction by lipopolysaccharide and tumor necrosis factor-alpha. J Infect Dis 1997; 175: 108-17.
27. SCHULTZ H, CSERNOK E, NIKKARI S, TOIVANEN P, TOIVANEN A, GROSS WL: BPIANCA is found in reactive arthritis caused by Yersinia and Salmonella infection and recognise exclusively the C-terminal part of the BPI molecule. Scand J Rheumatol 2000; 29: 226-31.
28. GHOSH K, PRADHAN V, GHOSH K: Background noise of infection for using ANCA as a diagnostic tool for vasculitis in tropical and developing countries. Parasitol Res 2008; 102: 1093-5.